Apotex Health Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024
Net Income	373.78	151.7	-146.92
Depreciation & Amortization	149.4	136.54	150.75
Other Amortization	13.13	12.05	7.72
Loss (Gain) From Sale of Assets	2.16	-1.59	-4.39
Asset Writedown & Restructuring Costs	72.28	8.02	-
Stock-Based Compensation	64.65	73.48	53.48
Other Operating Activities	-135.77	62.13	138.26
Change in Accounts Receivable	31.4	-104.97	-24.05
Change in Inventory	44.39	-58.1	310.51
Change in Accounts Payable	51.2	42.29	76.91
Change in Other Net Operating Assets	-25.64	232.88	8.64
Operating Cash Flow	640.96	554.41	570.9
Operating Cash Flow Growth	15.61%	-2.89%	-
Capital Expenditures	-121.06	-93.58	-83.26
Sale of Property, Plant & Equipment	4.9	16.7	-
Cash Acquisitions	-	-400.48	-2,586
Sale (Purchase) of Intangibles	-60.91	-150.51	-28.27
Investing Cash Flow	-177.07	-627.87	-2,697
Long-Term Debt Issued	968.51	717.69	-
Long-Term Debt Repaid	-138.53	-87.2	-82.94
Net Debt Issued (Repaid)	829.98	630.48	-82.94
Issuance of Common Stock	-	-	13.42
Repurchase of Common Stock	-140.95	-745.72	-200
Common Dividends Paid	-1,110	-163.95	-
Other Financing Activities	-62.86	-	-12.15
Financing Cash Flow	-483.46	-279.19	-281.67
Foreign Exchange Rate Adjustments	-1.41	9.26	3.33
Net Cash Flow	-20.98	-343.38	-2,405
Free Cash Flow	519.9	460.84	487.65
Free Cash Flow Growth	12.82%	-5.50%	-
Free Cash Flow Margin	14.89%	13.76%	16.58%
Free Cash Flow Per Share	2.69	2.43	2.73
Cash Interest Paid	207.07	156.85	107.98
Cash Income Tax Paid	179.85	273.66	111.6
Levered Free Cash Flow	468.34	487.86	-
Unlevered Free Cash Flow	614.99	621.39	-
Change in Working Capital	101.34	112.1	372.01